London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I am a holder so I hope this comes good. Is definitely unloved atm and I think will continue to drift. If so I will add more. Then with the right news investors will be clamouring for this hopefully. It is all a gamble
USA is where the money is not the UK, that's one route I'm sure CT is thinking of, either that or being taken private.
I agree, will all take time, meanwhile will drift I think....I am keeping an eye
I do wonder if the established product suppliers would do anything to destroy a future competitor such as Dest? It is puzzling why the mcap continues to fall, when the prospects and broker forecasts are so positive.
Https://www.weforum.org/agenda/2024/05/the-time-to-fight-antimicrobial-resistance-is-now/
I was alerted to this stock a few days ago.
And me and a few families aligned to me took a position this morning. Because I really like what I see (the possible/probable disconnect between VALUE and current Share Price).
And I like the biotech space very much.
I be but a semi-educated arbitrageur - I seek situations where there has become a disconnect between VALUE and current Share Price (SP). And I think that exists here.
In biotech, there are lots of snake-oil salesmen, so one has to be very careful, or one ends up in leprechaun-land.
Always look at 2 key factors: a) the quality of people involved and b) cash balance (do they have enough gas in the tank to make it to the Promised Land?).
This company seems to me to have both - Sir Nigel Rudd would not mess about with something that did not have true substance. He was one of the greatest corporate raiders ever - as an investment banker, I was often on the raid defence side against him.
I like this company and this stock. Very much.
Sefton ,I agree plus with resent news from the head of Fleming program ,right place,right time ?
Well put Sefton.
If you are new to Dest it is worth checking out AIM listed Ondine who have a competing product to Xf-73. also supposedly poised to enter phase 3, their product is probably better suited to the hospital enviroment where both will be used, not least because it only requires a single administration which is directly controlled by a clinician thus ensuring 100% compliance, whereas Xf-73 needs to be applied 5 times (on the same day).
Both co's are strapped for cash and neither is likely to escape further fund raising. When Dest are in a position to do a deal post a new phase 3 plan being accepted by the FDA, they will only have 3 months or so cash left which gives a lot of leverage to a potential partner, deals in the biotech sector are rarely negotiated on such fine timelines for this reason. So a prior fundraising is very likely imo to strengthen their negotiating position.
Al that said Dest still looks fair value at this price.
Also worth considering what will happen to the SP here IF the FDA don't accept outright DEST's very ambitious revised phase 3 plan for xf-73 (which is basically, if not actually in, then at least hovering around the door of the last chance saloon after 2 years of fruitless negotiations.) and ask for modifications to the plan and a resubmission.
A 50% drop from current levels and a very long diluted road back?
I very much doubt that Chris Tovey would have taken this gig on had he also not seen the huge potential.
I could name at least 50 companies at present with "potential" all in the penny syndrome. Potential is just a word for "maybe in a few years " a lot don't come to fruition and rely constantly on raising money, diluting shareholders while directors reap the benefit. Not saying that is the case here but there is definitely a struggle going on to get "the" deal.
Clearly getting a deal for XF-73 has proven harder than many expected a year ago, but the current share price reflects that. And let's not forget that a deal has been signed for the M3 product and it looks promising.
I’ve lost count of the companies I’ve been involved with who appoint a new CEO, credentials off the scale, only to find they’re in on the scam to bleed share holders dry. So here we are, massively underwater, a market that’s almost impossible to raise funds unless you do a GDR, POLX or AVCT style disastrous rase. Me thinks the new boy wonder is massively in over his head so expecting the worst unfortunately
Difficult to disagree with this prognosis. What to do? Stay in and risk losing everything or sell up while you can? This is a binary play. Only invest on actual good news not BS.
That's exactly the dilemma for me, Tatty99. I've resolved it by bailing out this afternoon. Took a cold bath on it, which has eaten up the majority of the juicy profits I had made on Destiny Pharma back in January. I haven't had a single biotech come good for me, Destiny was the only one... and now I've just lost a good chunk of my previous gains here.
I wish all remaining holders good luck - I genuinely do, because anyone clever enough, brave enough and lucky enough to have made money on these sorts of companies will have totally deserved it.
Ciao!
Certainly the biotech sector is out of favour at the moment, but that happens in the market,
sectors come and go, it`s all about Ai and tech , they`re flavour of the month, but bio will
come back, just got to hang in there.